Inactive Instrument

ISIS Pharmaceuticals, Inc. Nasdaq

Equities

US4643301090

Biotechnology & Medical Research

ISIS Pharmaceuticals, Inc. : Webcast Alert: Isis Pharmaceuticals Announces Its R&D Webcast Presentation

January 05, 2012 at 10:50 am EST

MarketScreener.com By

CARLSBAD, Calif., Jan. 5, 2012 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:


    What:                  Isis Pharmaceuticals' R&D Webcast Presentation
    When:                   Thursday, January 05, 2012 at 9:00 a.m. PT /
                            12:00 p.m. ET
    Where:                 www.isispharm.com
    How:                    Live on the Internet. Simply log on to our Web
                            site listed above.

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners. Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer. Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012. Isis' patents provide strong and extensive protection for its drugs and technology. Additional information about Isis is available at www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

Latest news about ISIS Pharmaceuticals, Inc.

Stifel Adjusts Ionis Pharmaceuticals Price Target to $53 From $50, Maintains Hold Rating	Jun. 27	MT
Ionis Pharmaceuticals' Shares Rise After FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	Jun. 25	MT
Ionis Pharmaceuticals Says FDA Accepts Metabolic Disorder Drug Candidate for Priority Review	Jun. 25	MT
Ionis Pharmaceuticals, Inc. Announces olezarsen FCS New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed	Jun. 25	CI
ANALYST RECOMMENDATIONS : Home Depot, Apple, Micron Technology, Anglo American, United Utilities...	Jun. 21
Ionis Pharmaceuticals Insider Sold Shares Worth $644,640, According to a Recent SEC Filing	Jun. 20	MT
Transcript : Ionis Pharmaceuticals, Inc. Presents at TD Cowen?s Genetic Medicines & RNA Summit, Jun-20-2024 03:30 PM	Jun. 20
Ionis Pharmaceuticals Says Otsuka Obtains Rights for Investigational Hereditary Angioedema Treatment in Asia Pacific	Jun. 18	MT
Ionis Pharmaceuticals, Inc. Announces Expand Licensing Agreement with Otsuka Pharmaceutical Co., Ltd	Jun. 18	CI
Investors need more time to assess Fed comments	Jun. 14
Bernstein Upgrades Ionis Pharmaceuticals to Market Perform From Underperform, Adjusts Price Target to $44 From $37	Jun. 14	MT
ANALYST RECOMMENDATIONS : Adobe, Bank of America, Boeing, Nvidia, Wise...	Jun. 14
Transcript : Ionis Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 through Jun-13-2024	Jun. 11
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	Jun. 06
Ionis Reports 'Positive Results' From Studies of Investigational Treatment for Hereditary Angioedema	May. 31	MT
Transcript : Ionis Pharmaceuticals, Inc. - Special Call	May. 31
Ionis Pharmaceuticals, Inc. Presents Positive Results from OASIS-HAE and OASISplus Studies of Investigational Medicine Donidalorsen in Patients with Hereditary Angioedema	May. 31	CI
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	May. 16	MT
Sector Update: Health Care Stocks Ease Thursday Afternoon	May. 16	MT
US Equity Indexes Trade Mixed as Investors Weigh Macro Data; Dow Touches Record High	May. 16	MT
Sector Update: Health Care	May. 16	MT
Dow Touches 40,000 Mark for First Time as Macroeconomic Data Signals Economic Weakness	May. 16	MT
Ionis Pharmaceuticals Says Potential Angelman Syndrome Therapy Improves Symptoms in Phase 1/2a Study	May. 16	MT
Stocks in motion: Walmart, Chubb, Deere...	May. 16
Sector Update: Health Care Stocks Steady Premarket Thursday	May. 16	MT

Chart ISIS Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâs products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Sector

Biotechnology & Medical Research

Calendar

2024-07-22 - ION582 Phase 1/2a HALOS Study Results Call

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+24.53%	47.96B
IQVIA HOLDINGS INC.	+1.95%	42.45B
LONZA GROUP AG	+44.76%	41.47B
ALNYLAM PHARMACEUTICALS, INC.	+28.48%	31.6B
ICON PUBLIC LIMITED COMPANY	+21.85%	28.63B
CELLTRION, INC.	-6.35%	28.03B
UNITED THERAPEUTICS CORPORATION	+52.50%	14.56B
MEDPACE HOLDINGS, INC.	+49.60%	14.14B
BIO-TECHNE CORPORATION	+3.83%	12.58B

Other Biotechnology & Medical Research